van Dijk AJ - Search Results

1

B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease.

Vooijs WC, Otten HG, van Vliet M, van Dijk AJ, de Weger RA, de Boer M, Bohlen H, Bolognesi A, Polito L, de Gast GC. Vooijs WC, et al. Among authors: van dijk aj, van vliet m. Br J Cancer. 1997;76(9):1163-9. doi: 10.1038/bjc.1997.528. Br J Cancer. 1997. PMID: 9365164 Free PMC article.

2

Transferrin toxin but not transferrin receptor immunotoxin is influenced by free transferrin and iron saturation.

Gosselaar PH, van-Dijk AJ, de-Gast GC, Polito L, Bolognesi A, Vooijs WC, Verheul AF, Krouwer HG, Marx JJ. Gosselaar PH, et al. Among authors: van dijk aj. Eur J Clin Invest. 2002 Mar;32 Suppl 1:61-9. doi: 10.1046/j.1365-2362.2002.0320s1061.x. Eur J Clin Invest. 2002. PMID: 11886434

3

Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies.

De Gast GC, Van Houten AA, Haagen IA, Klein S, De Weger RA, Van Dijk A, Phillips J, Clark M, Bast BJ. De Gast GC, et al. J Hematother. 1995 Oct;4(5):433-7. doi: 10.1089/scd.1.1995.4.433. J Hematother. 1995. PMID: 8581381 Clinical Trial.

4

CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma.

de Gast GC, Haagen IA, van Houten AA, Klein SC, Duits AJ, de Weger RA, Vroom TM, Clark MR, Phillips J, van Dijk AJ, et al. de Gast GC, et al. Among authors: van houten aa, van dijk aj. Cancer Immunol Immunother. 1995 Jun;40(6):390-6. doi: 10.1007/BF01525390. Cancer Immunol Immunother. 1995. PMID: 7543021 Free PMC article. Clinical Trial.

5

Identification of human ccn2 (connective tissue growth factor) promoter polymorphisms.

Blom IE, van Dijk AJ, de Weger RA, Tilanus MG, Goldschmeding R. Blom IE, et al. Among authors: van dijk aj. Mol Pathol. 2001 Jun;54(3):192-6. doi: 10.1136/mp.54.3.192. Mol Pathol. 2001. PMID: 11376134 Free PMC article.

6

High level of aneuploidy of chromosome 6 by FISH analysis of head and neck squamous cell carcinoma: limited applicability of LOH analysis to define HLA loss.

Koene GJ, Arts-Hilkes YH, van Dijk AJ, van der Ven KJ, Slootweg PJ, de Weger RA, Tilanus MG. Koene GJ, et al. Among authors: van dijk aj, van der ven kj. Hum Immunol. 2004 Dec;65(12):1455-62. doi: 10.1016/j.humimm.2004.06.012. Hum Immunol. 2004. PMID: 15603873

7

In vitro evidence for differential involvement of CTGF, TGFbeta, and PDGF-BB in mesangial response to injury.

Blom IE, van Dijk AJ, Wieten L, Duran K, Ito Y, Kleij L, deNichilo M, Rabelink TJ, Weening JJ, Aten J, Goldschmeding R. Blom IE, et al. Among authors: van dijk aj. Nephrol Dial Transplant. 2001 Jun;16(6):1139-48. doi: 10.1093/ndt/16.6.1139. Nephrol Dial Transplant. 2001. PMID: 11390712

8

HLA-DQB1 sequencing-based typing updated.

van Dijk A, Melchers R, Tilanus M, Rozemuller E. van Dijk A, et al. Tissue Antigens. 2007 Apr;69 Suppl 1:64-5. doi: 10.1111/j.1399-0039.2006.760_5.x. Tissue Antigens. 2007. PMID: 17445168

9

Role of human leucocyte antigen DQ in the presentation of T cell epitopes in the major cow's milk allergen alphas1-casein.

Ruiter B, Rozemuller EH, van Dijk AJ, Garssen J, Bruijnzeel-Koomen CA, Tilanus MG, Knol EF, van Hoffen E. Ruiter B, et al. Among authors: van dijk aj. Int Arch Allergy Immunol. 2007;143(2):119-26. doi: 10.1159/000098660. Epub 2007 Jan 16. Int Arch Allergy Immunol. 2007. PMID: 17228168

10

HLA-DRB sequencing-based typing: an improved protocol which shows complete DRB exon 2 sequences and includes exon 3 of HLA-DRB4/5.

van Dijk A, Melchers R, Hilkes Y, Rozemuller E, Tilanus M. van Dijk A, et al. Tissue Antigens. 2007 Apr;69 Suppl 1:61-3. doi: 10.1111/j.1399-0039.2006.760_4.x. Tissue Antigens. 2007. PMID: 17445167

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters